Ensifentrine

SAN DIEGO — Among patients with moderate to severe COPD, 24-week ensifentrine improved dyspnea, according to research presented at the American Thoracic Society International Conference.

When added to maintenance therapy for moderate to severe COPD, ensifentrine improves lung function and exacerbation rate vs. placebo, according to a draft evidence report by the Institute for Clinical and Economic Review.

Healio has compiled the most-read news in pulmonology posted in May.

WASHINGTON — Over 12 or 24 weeks, patients with COPD receiving ensifentrine showed improved measures of lung function, quality of life and exacerbation rate, according to an American Thoracic Society International Conference presentation.